In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA approves Medtronic's Captivia to deliver new Talent

This article was originally published in Clinica

Executive Summary

Medtronic's Captivia delivery system is now available in the US, after the FDA granted a premarket approval (PMA) supplement for its use with the firm's Talent thoracic stent graft. The Talent Captivia system is used to repair thoracic aortic aneurysms, bulges in the artery that can rupture if left untreated. Captivia is already available in Canada and Europe, where it is used to deliver the Valiant thoracic stent graft; however, Valiant is not yet approved in the US. The Talent stent has been available in the US since 2008 (, 25 April 2008), but was previously sold in smaller sizes and administered using another delivery system. Talent is now available in lengths up to 215mm.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts